Loading…
For deficient subjects: yes. For replete subjects: VITAL was mostly null — don't expect more than baseline correction.
VITAL found no major outcome benefit in replete adults; deficiency correction remains supported.
Our read is Partially Supported. The core mechanism holds and the direction is right, but the popular framing tends to overrun what the trials actually show. With a developing evidence base (68/100) and a working majority (72% consensus), taking vitamin D3 is reasonable for the right person at $5/month — just calibrate the expectation to the data, not the marketing.
Pulled the public claims about taking vitamin D3 from proponents on file (a tracked voice) and weighed them against the more cautious voices in the field, then cross-checked each against the primary trial and cohort literature and the prevailing clinical guidance. We grade the claim against what the human evidence actually supports, not against how confidently it is stated.
Downside risk on taking vitamin D3 is low at sensible doses, but low risk is not no risk: individual response varies, and a low-risk intervention is still only worth it if the benefit is real.
A large, long-duration RCT in a general population that either confirms a hard-outcome benefit or shows the effect washes out once it is properly controlled.
The effect size is large enough to matter clinically, not just statistically.
Mechanistic and trial evidence converge on a real, replicable effect.
Benefits hold across the populations where it's been tested.
Mechanistic and trial evidence converge on a real, replicable effect.
Benefits hold across the populations where it's been tested.
The headline effect shrinks once you account for trial quality.
Most of the support comes from short or small studies.
Most of the support comes from short or small studies.
Confounding and publication bias inflate the apparent benefit.
Animal-model results don't translate to the human protocol being recommended.